ANA/ENA Testing
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Covers clinical coverage, limitations, and scientific background for antinuclear antibody (ANA), extractable nuclear antigen (ENA) panels, anti-dsDNA, and certain proprietary/multianalyte lupus tests for Blue Cross Blue Shield - Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for ANA, ENA, anti-dsDNA, and Multianalyte Tests
Covered indications
Covered when ALL of the following are met:
Not medically necessary / exclusions
Not covered / limited scenarios:
Proprietary / multianalyte tests
Proprietary multianalyte tests and payer stance:
Contexts with demonstrated utility and guideline-concordant ordering
Clinical utility and guideline-informed contexts where testing is informative:
SLE classification and testing criteria
Classification and diagnostic criteria relevant to SLE-related testing:
The policy does not support routine use of cell-bound complement activation products (CB-CAPs) or proprietary multianalyte serum biomarker panels that report proprietary algorithm/index scores (for example, AVISE Lupus or Avise CTD) for diagnosis of systemic lupus erythematosus or connective tissue diseases. These tests do not meet coverage criteria in this document due to insufficient published evidence demonstrating required clinical benefit. Laboratories offering such assays should provide validation and clinical utility data if seeking coverage consideration.
ANA testing should not be used as a general screening test in asymptomatic individuals. Per Choosing Wisely and ACR guidance, do not order ANA as a screening test in patients without specific signs or symptoms of SLE or another connective tissue disease; ANA testing is appropriate only when there is clinical suspicion based on history and examination and documentation should reflect that suspicion.
For sclerosing skin diseases (for example localized scleroderma or systemic sclerosis), guidelines recommend against routine ANA screening. Testing for extractable nuclear antigens (ENA) should be reserved to confirm or exclude systemic sclerosis when clinically indicated rather than as a routine screen.
The provided document excerpts do not list additional explicit exclusion criteria beyond those noted for proprietary multianalyte tests and routine or screening use of ANA/ENA; no other specific absolute exclusions are described in the cited chunks.
Ordering specific autoantibody tests when the ANA is negative is generally not supported by coverage except in limited, defined circumstances. The policy allows exceptions for Anti-Jo-1 in a unique clinical subset of myositis and for Anti-SSA (Ro) when testing is clinically indicated in the setting of lupus or Sjögren’s syndrome; otherwise, testing specific antibodies with a negative ANA does not meet coverage criteria.
Routine repeat ANA testing after an initial negative result has low clinical utility and is discouraged. A retrospective study showed only 19% of patients converted to ANA-positive within two years after an initial negative repeat and this rarely changed diagnosis; therefore routine repeat testing and ordering of broad ANA subserologies without a positive ANA and supporting clinical findings is not indicated.
In pediatric patients, ANA and other autoantibody testing should not be ordered unless there is a strong clinical suspicion or specific signs of autoimmune disease. The American Academy of Pediatrics specifically advises against routine ANA testing in children without clear clinical indications.
Within the provided document excerpts there are no additional explicit statements labeled as 'not medically necessary' beyond the policy language already addressing testing of specific antibodies with negative ANA, repeat testing after a negative ANA, pediatric testing without suspicion, and the proprietary multianalyte/CB-CAP tests noted elsewhere.
Testing Thresholds and Coding-Adjacent Criteria
Provider Actions, Documentation, and Authorization Guidance
Prior authorization considerations for MAP/AVISE
Prior authorization considerations for multianalyte panels (MAP/AVISE): Payers may require prior authorization or clinical justification when MAPs or CB-CAPs (e.g., AVISE Lupus) are requested because these assays include proprietary algorithms and multianalyte indices. Clinical utility and analytic validation data (published studies showing reproducibility, predictive value, and impact on management) may be requested to support coverage. Evidence cited in the literature (eg, Dervieux et al., Ramsey‑Goldman et al., Wallace et al.) describing assay performance, reproducibility, and clinical impact should be available to support medical necessity.
- MAP/CB‑CAP tests (eg, AVISE Lupus) may prompt payer review for clinical utility and analytic validation data
- Provide published validation and clinical utility studies when requesting coverage or prior authorization
LDT validation and coverage review
LDTs are regulated under CLIA as high‑complexity laboratory‑developed tests and are not FDA‑cleared/approved. Payers may require documentation of laboratory validation, method description, and evidence of analytic performance when coverage is sought for LDTs.
- Laboratory‑developed tests (LDTs) are CLIA‑regulated; FDA clearance/approval is not required for clinical use
- Payers may request validation data (eg, precision, stability, reproducibility) and method details for in‑house assays
Situations triggering denial
Situations likely to trigger denial: testing without objective abnormal findings or strong clinical suspicion; screening during wellness visits or general encounters without abnormal results; testing ANA/ENA for nonspecific symptoms (eg, isolated fatigue or musculoskeletal pain) without other suggestive signs of autoimmune disease; ordering subserologies in the absence of a positive ANA and clinical suspicion.
- ANA/ENA testing during wellness or general encounters without abnormal findings — denial risk
- ANA/ENA testing for nonspecific symptoms alone (eg, fatigue, isolated musculoskeletal pain) — denial risk
- Ordering ANA subserologies without a positive ANA and clinical suspicion — denial risk
Unnecessary subserology testing risk
Unnecessary subserology testing risk: Do not order ANA subserologies (ENA panel or other specific autoantibody tests) unless there is a positive ANA and clinical suspicion of immune‑mediated disease. Excessive or reflexive subserology ordering without appropriate entry criteria increases likelihood of denial and inappropriate resource use.
- Do not order ANA subserologies without a positive ANA and appropriate clinical signs/symptoms
- Autoantibody panels ordered without evidence of rheumatic disease in children are discouraged
Inappropriate routine ordering risk
Inappropriate routine ordering risk: Routine or screening ANA and autoantibody testing in low‑pretest‑probability populations (including children without strong suspicion) is discouraged and may be denied. Repeat ANA testing after a confirmed negative result has low utility and frequently does not change diagnosis or management.
- Avoid routine ANA/autoantibody testing in patients without strong clinical suspicion (especially pediatric patients)
- Repeat ANA testing after a negative result generally has low utility and may be denied
Required clinical documentation
Required clinical documentation: Provide documentation demonstrating high clinical suspicion and objective findings consistent with autoimmune disease. Documentation should include relevant signs/symptoms that meet entry criteria (eg, for SLE: ANA ≥1:80 on HEp‑2 or equivalent, mucocutaneous findings, serositis, renal or neurologic findings), prior test results (including ANA titer and method), and how the test result will impact management.
- Document signs/symptoms that meet diagnostic entry criteria (eg, ANA ≥1:80 on HEp‑2 or equivalent when applicable)
- Include prior ANA/ENA/dsDNA results, specimen/test details, and intended clinical impact of results
- For MAP/CB‑CAP or LDT testing, include analytic validation references and rationale for use
Reflex testing guidance
Reflex testing guidance: Reflex ENA and anti‑dsDNA testing is appropriate for specific ANA patterns and titers (eg, nuclear homogeneous, speckled, Scl‑70-like, nucleolar, centromeric, cytoplasmic patterns) at defined titres (commonly >1:160) where identification of specific autoantibodies is clinically informative. Laboratories and ordering clinicians should follow staged algorithms to limit unnecessary downstream testing.
- Reflex ENA and anti‑dsDNA for specific ANA patterns (eg, homogeneous, speckled, Scl70‑like) at titres >1:160
- Execute targeted reflex tests rather than broad subserology panels when pattern/titer indicates specific antibodies
Step/sequence guidance for repeat testing
Step/sequence guidance for repeat testing and step therapy note: Routine repeat ANA testing after an initial negative result is not recommended due to low utility and high cost. No formal step‑therapy sequencing is specified in this policy; there are no required prior step‑therapy trials described for ANA/ENA/dsDNA testing beyond adherence to documented clinical criteria and, where applicable, any payer prior authorization process.
- Do not routinely repeat ANA after a confirmed negative result; repeat testing showed low yield within two years
- No step‑therapy sequencing is specified — adherence to documentation and prior authorization (if required) is the operational requirement
Background and Clinical Rationale
Antinuclear antibody (ANA) assays detect autoantibodies directed against intracellular antigens and are used as a screening tool for systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus, Sjögren’s syndrome, mixed connective tissue disease, systemic sclerosis, and inflammatory myopathies. Indirect immunofluorescence on HEp-2 cell substrate is the reference method because it provides pattern and titer information; solid-phase assays offer automation but test a narrower set of antigens, which can affect sensitivity and specificity depending on cutoffs and methods.
Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.